FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...
Overall these findings indicate that adding cabazitaxel to long-term androgen deprivation therapy and radiotherapy did not improve long-term outcomes and increased toxicity in men with high-risk ...
Scientists at McGill University and the Rosalind and Morris Goodman Cancer Institute have developed a new way to deliver cancer immunotherapy that caused fewer side effects compared to standard ...
PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.
The NHS has stated that cases of the deadly condition have a higher chance of being 'cured' if detected early.
New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...
The former 'Entertainment Tonight' co-host revealed in 2015 that he had been diagnosed with a rare form of prostate cancer ...
New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...
Oncology Media Relations oncology_media_relations@its.jnj.com Investor contact: Jessica Margevich investor-relations@its.jnj.com ...
Results from Blue Earth Diagnostics’ head-to-head study have been published in the European Journal of Nuclear Medicine and Molecular Imaging and were just presented at the 2026 ASCO Genitourinary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results